Recent Updates — MEDP

Medpace Holdings reported third-quarter revenue of $716.0 million, an 8.5% increase from the prior year period, with GAAP net income rising to $137.5 million or $4.84 per diluted share. Net new business awards grew 10.6% to $873.4 million, while EBITDA increased 16.0% to $172.1 million. Concurrently, the Board terminated the existing stock repurchase authorization with $527.0 million remaining and approved a new program authorizing up to $1.0 billion in share buybacks through December 31, 2028. The company operates as a global clinical contract research organization providing Phase I-IV development services.

Medpace Holdings, Inc. reported second quarter 2026 financial results, with revenue of $707.3 million, a 17.2% increase from $603.3 million in the prior-year period. GAAP net income for the quarter was $121.4 million, or $4.25 per diluted share, compared to $90.3 million, or $3.10 per diluted share, in the same period last year. The company forecasts 2026 full-year revenue in the range of $2.805 billion to $2.885 billion and GAAP net income between $494.0 million and $514.0 million. Medpace is a clinical contract research organization providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries.